Advanced Biological Laboratories (ABL) and Roche Diagnostics International
Signed a Collaboration Agreement to Promote their Next-Generation
Sequencing, Genotyping and Drug Resistance Products
LUXEMBOURG -- September 10, 2013
Advanced Biological Laboratories (ABL) today announced the signing of a
non-exclusive collaboration agreement with Roche Diagnostics International for
Europe, Middle East, Africa (EMEA) and Latin America (LATAM) territories.
This collaboration agreement is intended to develop a strategy to promote ABL
products especially its next-generation sequencing platform DeepChek® together
with Roche’s Next Generation Sequencing systems (GS Junior and GS FLX+
systems) for molecular virology. The principal objectives of the Collaboration
are to provide our mutual customers with integrated sequencing and analysis
systems delivering the required quality, sensitivity and meaningful genotyping
and drug resistance reporting for personalized healthcare.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world’s largest biotech company, with truly differentiated medicines in
oncology, infectious diseases, inflammation, metabolism and neuroscience.
Roche is also the world leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management. Roche’s personalised
healthcare strategy aims at providing medicines and diagnostic tools that
enable tangible improvements in the health, quality of life and survival of
patients. In 2012 Roche had over 82,000 employees worldwide and invested over
8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss
francs. Genentech, in the United States, is a wholly owned member of the Roche
Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For
more information, please visit www.roche.com.
Advanced Biological Laboratories (ABL), S.A., is a biotech company founded in
2000 as a spin-off from the European academic research center, CRP-Santé
Luxembourg and in 2004, acquired the control of TherapyEdge, Inc, a biotech
company spin-off from Triangle Pharmaceuticals, Inc. and in 2013 acquired the
Viral Hepatitis B & C related assets from EVIVAR MEDICAL, a biotech company
spin-off from Melbourne Health in Australia. ABL has a comprehensive suite of
healthcare management tools, including TherapyEdge®, ViroScore®, SeqHepB,
DeepChek® and VisibleChek®, which are used for data and patient management,
monitoring and personalized reporting applications. In 2012, ABL's products
received respectively CE-marking and IVD certifications. ABL's products offer
infectious disease clinicians and virology laboratories optimal and efficient
IT solutions, for sequencing, clinical genotyping and drug resistance
analysis, including powerful fully integrated databases and analysis systems
combining standard and high-throughput Next Generation Sequencing data. The
clinical and biological outcomes aid in the generation of clinically
meaningful genotyping reports for personalized healthcare.
All trademarks used or mentioned in this release are protected by law.
Advanced Biological Laboratories
Dr Chalom Sayada, +352 2638 8921
CEO ABL SA
Press spacebar to pause and continue. Press esc to stop.